PT-141 - 10 mg (Bremelanotide / Melanocortin Receptor Agonist)

1. Central Nervous System Activation -MC3R & MC4R Pathways

PT-141 crosses the blood–brain barrier and binds to melanocortin 3 and 4 receptors in the hypothalamus, the region controlling arousal and energy. This receptor stimulation:

• Activates dopaminergic and hypothalamic signaling associated with sexual desire
• Increases neuronal excitability in arousal centers without affecting vascular tone
• Enhances motivation, libido, and mood balance in research models

This makes PT-141 a leading compound in neuroendocrine and sexual-function research.

2. Distinct from Vasodilatory Mechanisms

Unlike phosphodiesterase inhibitors (e.g., sildenafil), PT-141 works centrally, not through blood-flow pathways. It:

• Does not rely on nitric-oxide or vascular relaxation
• Functions via CNS neurochemical activation
• Has no direct cardiovascular stimulation, allowing researchers to isolate its neuromodulatory effects

This central mechanism differentiates PT-141 as a pure neuro-receptor peptide, ideal for cognitive and behavioral-response studies.

3. Mood, Energy & Motivation

Because melanocortin receptors also play roles in stress and mood regulation, PT-141 has been studied for its effects on:

• Energy enhancement and reduced fatigue
• Mood elevation through dopaminergic stimulation
• Motivational drive and reward-system activation

This places PT-141 within a broader research context beyond sexual function -into CNS performance, emotional regulation, and behavioral response.

• Neuroendocrine and sexual-function pathway research
• CNS dopaminergic and melanocortin-system studies
• Behavioral and motivational-response models
• Mood, stress, and reward-signaling investigations
• Comparative studies vs α-MSH analogues (e.g., Melanotan II)

PT-141 (Bremelanotide) -10 mg Lyophilized Peptide Powder

PT-141 (10 mg) — Research Dosage Guidance

Reconstitution (Mixing)

• Add 2 ml Bacteriostatic Water to the vial
• Roll gently between palms (do not shake)
• Store reconstituted vial in the refrigerator (2–8 °C)

Concentration Calculation

10 mg ÷ 2 ml = 5 mg/ml

Every 10 insulin units (0.1 ml) = 0.5 mg (500 mcg)

Core Dosage Guidelines

For libido, mood, and energy-pathway research

Standard research dose: 500 mcg – 2 mg per injection

Typical starting dose: 500 mcg (0.1 ml / 10 units)

Maximum single dose: 2 mg (0.4 ml / 40 units)

Administration: Subcutaneous (abdomen or thigh)

Timing: Inject 45–60 minutes before the desired effect window

Syringe Measurement Guide
Dose    Volume (ml)    Insulin Units
250 mcg    0.05 ml    5 units
500 mcg    0.10 ml    10 units
1 mg    0.20 ml    20 units
2 mg    0.40 ml    40 units

Reference: Every 10 units (0.1 ml) = 500 mcg PT-141

Targeted Research Protocols (Different Situations)
1.⁠ ⁠Libido Initiation / First-Exposure Research

• (Sensitivity assessment, response profiling)
• Dose: 500 mcg
• Frequency: As needed
• Timing: 45–60 minutes prior
• Notes: Preferred starting protocol to assess tolerance

2.⁠ ⁠Standard Libido & Sexual-Response Research

(Male & female arousal, desire, and response models)

• Dose: 1 mg
• Frequency: As needed
• Timing: 45–60 minutes prior
• Notes: Most commonly used research dose

3.⁠ ⁠Reduced-Response / Advanced Libido Research

• (Lower responder models, refractory libido)
• Dose: 1.5 – 2 mg
• Frequency: As needed
• Timing: 45–60 minutes prior
• Notes: Advanced protocol; monitor for nausea or flushing

4.⁠ ⁠Mood & Motivation Pathway Research

• (Melanocortin-mediated mood and reward signaling)
• Dose: 500 mcg – 1 mg
• Frequency: 1–2× weekly
• Timing: Morning or early evening
• Notes: Lower doses often sufficient for mood effects

5.⁠ ⁠Energy & Drive Modulation Research

• (Central motivation, vitality signaling)
• Dose: 500 mcg – 1 mg
• Frequency: 1–2× weekly
• Timing: Morning preferred
• Notes: Non-stimulant mechanism

Cycle & Frequency Guidelines

Use as needed

Do not exceed: Once per 24 hours

Typical research cycle: 2–3× weekly

Rest period: Allow ≥24 hours between doses

Key Research Benefits

• Activates melanocortin receptors MC3R & MC4R
• Enhances libido and sexual response in male and female models
• Supports mood and motivational signaling
• Non-hormonal and independent of nitric-oxide pathways
• Distinct mechanism compared to PDE-5 inhibitors

Important Notes

Always use sterile needles and alcohol swabs

Do not reuse or share needles

Store reconstituted peptide at 2–8 °C

For research use only

Possible dose-dependent effects:

Temporary flushing

Mild nausea

Headache in sensitive research models

PT-141 (Bremelanotide) is a melanocortin-receptor agonist that influences central arousal, autonomic, and vascular signaling. Use caution or avoid in the following research contexts:

Uncontrolled hypertension or cardiovascular disease models (transient blood-pressure or heart-rate changes possible)

Pregnancy or lactation models (no safety data available)

Migraine or vascular-headache–sensitive models (vasodilation may exacerbate symptoms)

Severe nausea disorders or gastric-sensitivity models (dose-dependent nausea reported)

Active melanoma or atypical mole disorders (shared melanocortin pathways may confound dermatologic outcomes)

Moderate to severe hepatic or renal impairment (slower clearance may enhance side effects)

PT-141 is a centrally acting melanocortin receptor agonist used in research on libido, motivation, and neurovascular signalling. Most side effects are mild and short-lived, including nausea, flushing, headache, or itchy welts at the injection site. Proper dilution, gradual titration, and hydration significantly improve comfort and reliability in controlled studies.